Asked by: Nadia Whittome (Labour - Nottingham East)
Question to the Foreign, Commonwealth & Development Office:
To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, with reference to her Department's document entitled FCDO archive inventory, updated on 12 March 2025, what steps her Department is taking to review and make available records relating to policy in Palestine, including UID 1454 and 1790.
Answered by Hamish Falconer - Parliamentary Under-Secretary (Foreign, Commonwealth and Development Office)
Last year, the UK made the historic decision to recognise the state of Palestine, noting that our commitment to supporting long-term peace stems not only from the current crisis but also from our historic responsibility to the region's security. Available materials about the UK's role during the Mandate for Palestine can be readily accessed from the National Archives.
Asked by: Nadia Whittome (Labour - Nottingham East)
Question to the Foreign, Commonwealth & Development Office:
To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, what assessment she has made of the potential implications for her policies on the Israel-Palestine conflict of the UK's role during the Mandate for Palestine.
Answered by Hamish Falconer - Parliamentary Under-Secretary (Foreign, Commonwealth and Development Office)
Last year, the UK made the historic decision to recognise the state of Palestine, noting that our commitment to supporting long-term peace stems not only from the current crisis but also from our historic responsibility to the region's security. Available materials about the UK's role during the Mandate for Palestine can be readily accessed from the National Archives.
Asked by: Nadia Whittome (Labour - Nottingham East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help (a) ensure that the BREAKWATER treatment protocol for patients with BRAF‑mutated bowel cancer is evaluated and funded as a matter of urgency, and (b) secure equal access to this protocol for patients across the UK.
Answered by Zubir Ahmed
The National Institute for Health and Care Excellence (NICE) makes recommendations for the National Health Service on whether new licensed medicines and licence extensions for existing medicines should be routinely funded by the NHS based on an assessment of clinical and cost effectiveness. NICE aims wherever possible to issue guidance for the NHS on new medicines close to the time of licensing, and cancer drugs are eligible for funding from the point of a positive draft NICE recommendation.
The BREAKWATER study is investigating encorafenib, a BRAF inhibitor, in combination with cetuximab and fluorouracil-based chemotherapy for the potential treatment of colorectal cancer. This regimen does not currently have a United Kingdom marketing authorisation for use in the treatment of previously untreated BRAF V600E mutation positive metastatic colorectal cancer. NICE has prioritised an appraisal of encorafenib for this indication in anticipation of it being granted a UK marketing authorisation and will schedule the appraisal so that guidance can be published as close as possible to the expected licensing date. Further information on the appraisal’s status is publicly available on NICE’s website at the following link:
https://www.nice.org.uk/guidance/awaiting-development/gid-ta11961
The clinical trial was assessed and approved in the UK and is currently active, with further information available at the following link:
https://clinicaltrials.gov/study/NCT04607421?term=BREAKWATER&viewType=Card&rank=1